Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Abroad (travel likely)RecruitingPHASE2

Conditions

Cytokine Release Syndrome · Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Study coordinator (Naresh Bumma, MD) · Naresh.Bumma@osumc.edu · 614-293-6307
Contact: Principal Investigator (Naresh Bumma, MD)

Study leads

Naresh Bumma, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

CRS - Cytokine Release Syndrome · Myeloma

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Lymphoma · Myeloma · Cytokine Release Syndrome

Abroad (travel likely)Recruiting

Salt Lake City, United States

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Denver, United States

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Ampang, Malaysia